This Electromedical Breakthrough Could Disrupt The $300 Billion Dollar Diabetes Market

Microcurrent technology has the potential to transform healthcare and completely disrupt the $300 Billion Diabetes Market[1].

There are 34.2 million Americans with diabetes. That’s 10.5% of the US population — with no solution in sight. That’s just over 1 in 10 people living with diabetes.[2] Another 88 million American adults — approximately 1 in 3 — have prediabetes and are at risk of developing diabetes and all the related complications that go with it.[3]

Diabetes is a health tsunami in both Canada and the USA — it’s a public health crisis like few others. Big pharma knows this and has been cashing in on it for years.

Could microcurrent replace diabetes and pain medications?

Big players like Boston Scientific (NYSE:BSX) and Medtronic plc (NYSE:MDT) seem to think so. With a market expected to grow at a CAGR of 7.9% to reach USD 25.20 Billion by 2021 and USD 38.13 Billion by 2026 you can see why.[5,6],

Boston Scientific and Medtronic have a long history in bioelectronics with pacemakers and spinal cord stimulation devices. A day after taking out a loan from Medtronic, Saluda Medical brought in $75 million with an equity round joined by Boston Scientific to invest in a neuromodulation device to treat back pain.[7]

GlaxoSmithKline (NYSE:GSK) and Google parent Alphabet’s life sciences unit developing a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting the novel field of medicine called bioelectronics.[8]

The common theme with the big players is that their solutions are invasive. 

Bioelectric Medicine Is The Wave Of The Future

Microcurrent is at the Forefront of the Electroceutical Healthcare Movement. This Medical Therapy was Featured in the Health & Medicine Section of Time Magazine — Highlighting Bioelectric Medicine’s Incredible Potential:

“ While some bioelectronic, or electroceutical, therapies already exist to treat conditions such as headaches, certain cases of depression, as well as chronic and sinus pain, the new wave of electricity-based strategies could expand to help people with some of the most widespread chronic diseases in the world, including high blood pressure, arthritis, diabetes, some forms of blindness and even dementia.”

Time Magazine[4]


Cell MedX (OTCQB: CMXC) an early-stage company focused on the discovery, development and commercialization of therapeutic microcurrent products announced that its wholly-owned subsidiary has received Health Canada Class II Medical Device Licenses for their eBalance Home System and eBalance Pro System —and is on track to file for FDA approval in early 2021.

Cell MedX May Have a Solution

Cell MedX, a research and development company publicly traded on the OTC Markets under the symbol CMXC, has entered the microcurrent market. The company has received Class II Medical Device Licenses for both its eBalance Home System and eBalance Pro System from Health Canada. Both systems are approved for general wellness and pain. The company is planning further studies to look at the use of microcurrent for diabetes and high blood pressure.

Cell MedX’s eBalance technology is safe, non-invasive and addresses chronic pain. Because the company is at an early stage, it offers an opportunity investors covet. You can be sure the big players will be watching closely as it tackles two big markets and navigates through the necessary regulatory approvals to bring medical microcurrent devices and systems to market.

Microcurrent may be the answer the world is waiting for. It’s safe, effective, non-invasive and drug-free. No insulin. No painkillers. Just sweet, clean, frequency-specific microcurrent.

The Cost of Insulin is On the Rise

In 1923, the discoverers of insulin sold their patent for $1, hoping the low price would keep the essential treatment available to everyone who needed it. Today, retail prices in the US are around the $300 range for all insulins, and are controlled by the three major brands. Even adjusting for inflation, that’s a price increase of over 1,000%. Stories of Americans rationing insulin – and dying for it – have been making national headlines.[9]

In the past 15 years, insulin prices have tripled and it’s the insulin manufacturers who set the price. There’s no limit to how high the price can be set and they don’t have to disclose how they set it.[10]  

The big three understand the huge dollars involved in treating diabetes — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), and Sanofi (NASDAQ:SNY) control 90% of the world’s insulin market.[11]   

Could Microcurrent Be the Solution We’ve Been Waiting For?

Now, this early-stage biotech company may offer a novel breakthrough treatment that could level the playing field for those living with diabetes, and empower patients to take back their health from big pharma.

Cell MedX (OTCQB: CMXC), has developed two new revolutionary microcurrent systems that may treat diabetes at a cellular level.

Cell MedX’s introduction of the eBalance Home System & eBalance Pro System in Canada — and planned introduction in the USA upon FDA approval —brings to market a powerful non-invasive drug-free therapeutic option for some of the most widespread chronic diseases in the world.

eBalance delivers microcurrent — specific algorithms of low amplitude microcurrent — through the skin. The human body possesses an endogenous bioelectric system. Microcurrent works synergistically with the body’s own biological electrical system to energize cells and aid in healing.[12]  

Microcurrent Has Been Studied in Diabetes, Hypertension & Chronic Wound Care

Studies have been done by researchers on microcurrent in the management of diabetes, hypertension and chronic wounds with positive results. Further R&D on microcurrents is looking at how central microcurrents are to both the treatment and the potential reversal of Type 2 diabetes.[13]

10 Reasons Why Cell MedX (OTCQB: CMXC) Could Turn Out To Be The Best Pure-Play In The Bioelectric Healthcare Field

Bioelectric Medicine is Groundbreaking

Microcurrent Technology is groundbreaking and innovative but it’s not uncharted territory. It is being talked about in mainstream media like Time Magazine. And it is no wonder, this scientific treatment has a long history being used to treat chronic pain and help heal wounds. Benjamin Franklin, one of America’s Founding Fathers and a discerning patient, used electrical currents for his many ailments including pain relief from frozen shoulder.[18]  

Microcurrent technology has come a long way since then. It’s a hot secret weapon for elite athletes. Terrell Owens, celebrated All-Pro wide receiver for the Philadelphia Eagles credits microcurrent therapy as a main reason he was playing instead of watching the 2005 Super Bowl from the sidelines. He shocked the football world by being in top playing shape just six weeks after a major surgery that should have taken 16-18 weeks of recovery.[19]   

Cell MedX is in an enviable position with two Health Canada Class II Medical Device Approvals in 2020 and an imminent FDA submission for their eBalance Home System and eBalance Pro System. 

Their state-of-the-art microcurrent technology has undergone rigorous testing. Both eBalance Systems are now Approved as Class II Medical Devices that deliver a proprietary “prescription” of pre-programmed, easy-to-use treatment options chosen with the push of a button.

The Huge Cost of Diabetes

Since the 1980s, diabetic neuropathy and non-healing wounds have been successfully treated using microcurrent. Neuropathy is a side effect of diabetes. It’s when the brain misfires and causes tingling or severe pain in the hands and feet. For those who suffer from it, it can be crippling.[20]  

Beyond the discomfort of crippling pain, neuropathy leads to amputation. The Cleveland clinic estimates that each year about 86,000 Americans with diabetes lose a limb. The sad sequence of events leading up to amputation is typically:

  • Diabetes causes high sugar levels that cause nerve damage.
  • The nerve damage reduces sensation in the limbs (usually the feet), which can lead to unnoticed injuries turning into skin ulcers or infections.
  • About 1 in 4 people with diabetes will suffer foot ulcers, which are painful sores on the feet. Reduced blood flow to the feet, another effect of diabetes, prevents the wound from healing properly.
  • The wounds cause the tissue in the foot or leg to break down, requiring amputation.
  • Left untreated, diabetes leads to non-healing wounds and amputations. In the American Journal of Managed Care, they estimate that there are about 230 amputations each day in the United States as a result of diabetes.[21]

Managing the disease, the complications and the financial pressures of diabetes is no picnic. Beyond the non-healing wounds and amputations, it’s an uphill battle for people living with diabetes. Their high sugars weaken their immune system putting them at greater risk of infection from sepsis and everything from the common flu to Covid-19.[22]   

Their bodies have to fight so much harder just to ward off things you and I take for granted. We’ve all heard that diabetes-related complications from high sugars can be disabling and even life-threatening.

What if there was something that could turn those numbers around? Lower those sugars and boost the immune system as a result? Microcurrent technology may be the answer we’ve all been waiting for.

Up to now, not many studies had been done on using microcurrent to treat chronic conditions like diabetes. That’s because of the huge regulatory burden and cost. Trials are expensive and getting Health Canada or FDA approval is easier said than done. But Cell MedX (OTCQB: CMXC) is doing just that!

Cell MedX (OTCQB: CMXC) Is Getting Real Results In Real Trials With Real People

A 3-month observational clinical trial was conducted to assess eBalance used twice weekly as an adjunct treatment for diabetes and diabetes-related complications. The trial was approved by Health Canada and conducted by a third-party. It confirmed safety and revealed clinically significant results:

After 7-weeks of eBalance treatments, the study showed an average daily fasting blood glucose level decline of 12.3% from 10.5 to 9.2 mmol/L. In that same study, mean HbA1c levels declined by 0.16% from 8.36% to 8.20%, a drop of 1.91%. These results are clinically significant both in terms of patient care and lowering the risk of long-term diabetes-related complications. HbA1c is the gold standard for measuring sugars over a three-month period. It is the measure used to measure the risk of long-term diabetes complications.

The trial confirmed clinical benefit, safety and areas that warrant additional investigation. Based on the promising results, larger scale, randomized clinical trials are planned when the company receives their Class II Medical Device designation in both Canada & the USA.

The trial showed positive results for those suffering from diabetes. But researchers also observed other positive results in blood pressure, kidney function, improvement in pain and numbness — and patients reporting that they have never slept better.

Why it Matters

One of the largest diabetes clinical trials ever conducted, the UK Prospective Diabetes Study (UKPDS) showed that for every 1% reduction in HbA1c, the relative risk for:

Both the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT) showed that improving HbA1c by just 1% for individuals with Type 1 or Type 2 diabetes lowers their risk of combined microvascular complications by 25%.

People with Type 2 diabetes who reduce their HbA1c level by 1% are:

Cell MedX (OTCQB: CMXC) 2020 Highlights

It has been a banner year for Cell MedX. They completed a successful Medical Device Single Audit Program (MDSAP) audit in February 2020 and received both MDSAP and their ISO 13485:2016 certification in June 2020. Their successful MDSAP Audit and certification means that Cell MedX has met the rigorous regulatory requirements of a medical device manufacturer, in this case for the jurisdictions of Canada & the USA.

They are poised for an imminent FDA submission as a Class II Medical Device which they expect to file in early 2021. This comes fast on the heels of the company receiving Health Canada Class II Medical Device System approval for both their eBalance Home System and eBalance Pro System this year. [24,25]  

This Early-Stage Development Company Has Been Busy

Over the past 4 years, Cell MedX has been actively advancing research in the use of eBalance microcurrent technology through their therapeutic device development, safety testing and observational clinical studies.

Cell MedX has shown tremendous commitment in putting their eBalance technology through the paces — from rigorous testing to ongoing clinical studies that meet regulatory standards.

Cell MedX have their Certificate of Conformity as a Class A (Professional Use Device) and Class B (Home Use Device) from LabTest Certification Inc. To qualify, eBalance was tested against CSA, CE and UL standards for electrical safety and emissions meeting the Canadian Health Standard.

Cell MedX holds a Class I Establishment License from Health Canada for their proprietary ePro Gel.

Driven by Passion

The founders of Cell MedX (OTCQB: CMXC) are driven to bring microcurrent to the forefront of diabetes care. This is a skilled team driven to make the company a leader in electroceutical medicine. With that kind of passion and the success they’ve seen so far, we’re excited to watch. It’s not every day you can jump on board a start-up with this kind of potential.

Learn More About CMXC As News Comes Out at Your Preferred Brokerage Firm


This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor’s reliance on the use of this material. Financials Trend has been compensated 3.1k for coverage of this stock by Think Ink Marketing on behalf of Cell MedX this month. Financials Trend and its affiliates or officers currently hold no shares of this stock. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.